Lazard Asset Management
CBIO

Lazard Asset Management’s Crescent Biopharma CBIO Stock Holding History

Lazard Asset Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-484
Closed -$696K – 1055
2018
Q3 		$696K Buy
+484
New +$732K ﹤0.01% 792
2018
Q2 		– Sell
-162
Closed -$262K – 1063
2018
Q1 		$262K Buy
+162
New +$337K ﹤0.01% 816

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Lazard Asset Management's CBIO Position: Q4 2018 in Review

Lazard Asset Management sold out of Crescent Biopharma (CBIO) in Q4 2018, closing a stake of 484 shares — an estimated $696K sold.

Lazard Asset Management first reported a position in CBIO in Q1 2018 and held it in 2 quarters. The position peaked at $696K in Q3 2018. 81 funds tracked by Wall St. Rank hold CBIO as of Q4 2018.

  • Lazard Asset Management reported no remaining Crescent Biopharma position as of Q4 2018 after selling out during the quarter.
  • Lazard Asset Management sold 484 Crescent Biopharma shares in Q4 2018, an estimated $696K.
  • Lazard Asset Management first reported a position in Crescent Biopharma in Q1 2018 and held it in 2 quarters.
  • Lazard Asset Management's Crescent Biopharma position peaked at $696K in Q3 2018.
  • 81 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2018.

Based on Lazard Asset Management's 13F filing for Q4 2018, filed 13 Feb 2019.